Maze Therapeutics (MAZE) closed at $36.09 on November 12, 2026, down 1.7% from the previous close, on volume of 435,105 shares (30-day average 690,870).
Data as of November 12, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 12, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Tue, 10-Nov 3:25 PM ET)
Maze Therapeutics’ MZE829 Progress and 2027 Catalysts Support Upside Despite Valuation Gap
TipRanks (Tue, 10-Nov 8:15 AM ET)
Canaccord Genuity Remains a Buy on Maze Therapeutics, Inc. (MAZE)
TipRanks (Tue, 10-Nov 7:36 AM ET)
Maze Therapeutics, Inc. (MAZE) Gets a Buy from Wells Fargo
TipRanks (Tue, 10-Nov 7:36 AM ET)
TipRanks (Tue, 10-Nov 6:46 AM ET)
Analysts Are Bullish on Top Healthcare Stocks: Myomo (MYO), Maze Therapeutics, Inc. (MAZE)
TipRanks (Tue, 10-Nov 6:40 AM ET)
Maze Therapeutics GAAP EPS of -$0.79
Seeking Alpha News (Tue, 10-Nov 5:22 AM ET)
Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Globe Newswire (Mon, 9-Nov 4:05 PM ET)
Maze Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 3-Nov 7:00 AM ET)
Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
Globe Newswire (Tue, 6-Oct 4:05 PM ET)
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Maze Therapeutics trades on the NASDAQ stock market under the symbol MAZE.
As of November 13, 2026, MAZE stock price declined to $34.43 with 1,005,052 million shares trading.
MAZE has a beta of 0.67, meaning it tends to be less sensitive to market movements. MAZE has a correlation of 0.02 to the broad based SPY ETF.
MAZE has a market cap of $1.88 billion. This is considered a Small Cap stock.
Last quarter Maze Therapeutics reported $0 in Revenue and -$.79 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.03.
The top ETF exchange traded funds that MAZE belongs to (by Net Assets): VTI, IWM, XPH, VXF, IWO.
MAZE has underperformed the market in the last year with a return of +5.7%, while SPY returned +11.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in MAZE shares. However, MAZE has outperformed the market in the last 3 month and 2 week periods, returning +25.1% and +7.8%, while SPY returned -2.3% and -2.1%, respectively. This indicates MAZE has been having a stronger performance recently.
MAZE support price is $34.79 and resistance is $37.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MAZE shares will trade within this expected range on the day.
